NIP
SLN

Nicholas Investment Partners’s Silence Therapeutics SLN Stock Holding History

Nicholas Investment Partners’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-150,480
Closed -$2.86M – 243
2024
Q2 		$2.86M Buy
+150,480
New +$3.2M 0.3% 124

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $957M AUM 35.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Nicholas Investment Partners's SLN Position: Q3 2024 in Review

Nicholas Investment Partners sold out of Silence Therapeutics (SLN) in Q3 2024, closing a stake of 150,480 shares — an estimated $2.86M sold.

Nicholas Investment Partners first reported a position in SLN in Q2 2024 and held it in 1 quarter. The position peaked at $2.86M in Q2 2024. 69 funds tracked by Wall St. Rank hold SLN as of Q3 2024.

  • Nicholas Investment Partners reported no remaining Silence Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Nicholas Investment Partners sold 150,480 Silence Therapeutics shares in Q3 2024, an estimated $2.86M.
  • Nicholas Investment Partners first reported a position in Silence Therapeutics in Q2 2024 and held it in 1 quarter.
  • Nicholas Investment Partners's Silence Therapeutics position peaked at $2.86M in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Silence Therapeutics as of Q3 2024.

Based on Nicholas Investment Partners's 13F filing for Q3 2024, filed 12 Nov 2024.